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loom’s syndrome (BS) is a rare genetic disorder
characterized by a broad range of symptoms and,
most importantly, a predisposition to many types of
cancers. Cells derived from patients with BS exhibit an
elevated rate of somatic recombination and hypermutability,
supporting a role for bleomycin (BLM) in the maintenance
of genomic integrity. BLM is thought to participate in
several DNA transactions, the failure of which could give
raise to genomic instability, and to interact with many proteins
involved in replication, recombination, and repair. In this
study, we show that BLM function is speciﬁcally required
to properly relocalize the RAD50/MRE11/NBS1 (RMN)
complex at sites of replication arrest, but is not essential in
B
 
the activation of BRCA1 either after stalled replication forks
or 
 
 
 
-rays. We also provide evidence that BLM is phosphory-
lated after replication arrest in an Ataxia and RAD3-related
protein (ATR)-dependent manner and that phosphorylation
is not required for subnuclear relocalization. Therefore, in
ATR dominant negative mutant cells, the assembly of the
RMN complex in nuclear foci after replication blockage is
almost completely abolished. Together, these results suggest
a relationship between BLM, ATR, and the RMN complex
in the response to replication arrest, proposing a role for
BLM protein and RMN complex in the resolution of stalled
replication forks.
 
Introduction
 
Cells have evolved several genes to maintain genomic integrity
and stability. In mammals, the failure of the complex molecular
pathways ensuring genomic stability almost inevitably leads to
cancer. Despite the importance of the precise knowledge of
these pathways, little is known about the precise mechanism
by which genomic integrity is maintained in mammalian
cells, and in particular in human cells. Recently, it has been
proposed that a class of DNA helicases, related to the bacte-
rial RecQ helicase, plays an important role in the molecular
pathways leading to genetic stability (Chakraverty and Hickson,
1999). Whereas 
 
Escherichia coli
 
 and yeast genomes encode
only one RecQ helicase, which is essentially involved in the
control of recombinational processes (Watt et al., 1996;
Hanada et al., 1997; Myung et al., 2001) and also in yeast in
chromosome segregation (Watt et al., 1995), human cells
have multiple RecQ-class helicases. Five human RECQ
genes have been cloned and, among these, three are correlated
to genetic diseases: WRN, mutated in Werner’s syndrome;
RTS, mutated in Rothmund-Thomson syndrome; and BLM,
found mutated in Bloom’s syndrome (BS)* (Mohaghegh and
Hickson, 2001).
Bloom’s syndrome is a rare genetic disorder characterized
by a broad range of symptoms and, most importantly, a pre-
disposition to many types of cancers (German, 1995). Cells
derived from patients with BS exhibit elevated frequency
of chromosome and chromatid breaks, chromatid ex-
changes, and sister chromatid exchanges (SCEs) (Mc-
Daniel and Schultz, 1992; Neff et al., 1999), in addition
to increased levels of locus-specific mutations (German,
1995). Such hypermutability strongly supports a role for
BLM in the maintenance of genomic integrity. In fact,
BLM is thought to participate in several DNA transactions,
the failure of which could give rise to genomic instability,
such as recombination, replication, and repair (Hickson
et al., 2001). Consistent with a proposed role in recom-
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bination in somatic cells, BLM can bind Holliday junc-
tions (Karow et al., 2000; Mohaghegh et al., 2001) and
D-loops (van Brabant et al., 2000), and physically interact
with the RAD51 recombinase (Bischof et al., 2001; Wu
et al., 2001). In addition, BLM can also interact with one
topoisomerase III isoform, TOPOIII
 
 
 
, and this interac-
tion could be important for BLM’s role in controlling re-
combination (Johnson et al., 2000; Wu et al., 2000b).
Recently, it has also been reported that BLM interacts
with several proteins involved in either DNA repair or
DNA damage signalling, such as BRCA1, MRE11, and
ATM to form a surveillance complex, called BASC, that
could function as a sensor for various types of DNA le-
sions or aberrant structures (Wang et al., 2000). BLM
protein seems to relocalize to nuclear structures contain-
ing BRCA1 and/or the complex formed by RAD50/
MRE11/NBS1 (RMN) complex, either after hydroxyurea
(HU)-induced replication arrest or ionizing radiation–
induced DNA damage (Wang et al., 2000). Furthermore,
BLM itself is able to relocalize after DNA damage (Bis-
chof et al., 2001; Wu et al., 2001), also interacting with
another protein possible involved in genomic stability,
PML (Ishov et al., 1999; Bischof et al., 2001). However,
despite the possible crucial role for BLM in the pathways
controlling genetic stability the knowledge of its func-
tions is still incomplete.
In this study, we investigated whether the absence of an
active BLM protein could give rise to abnormal response of
the BRCA1 protein and the RMN complex, two of the pro-
posed molecular partners of BLM, either after HU-induced
replication fork stall or ionizing radiation–induced DNA
damage. In addition, we examined the possibility that BLM
phosphorylation by the ATM/Ataxia and RAD3-related
protein (ATR) kinases could be important for subnuclear re-
localization after replication arrest or DNA damage.
We found that BLM was essential to correctly relocalize
and activate the RMN complex after replication arrest, but
not after 
 
 
 
-rays. On the contrary, an active BLM protein
was not crucial in BRCA1 phosphorylation and focus-
forming activity, either after replication arrest or 
 
 
 
-rays.
We also found that BLM phosphorylation after HU was
essentially ATR dependent, but that it is unrelated to BLM
subnuclear relocalization. Furthermore, lack of BLM phos-
phorylation determined a dramatic decrease of the RMN
foci after HU, suggesting a possible role for BLM protein
in organizing RMN foci after replication arrest.
 
Results
 
BS cells show defective formation of RMN complex 
foci and absence of NBS1 phosphorylation upon HU 
treatment, but not after 
 
 
 
-irradiation
 
It has been recently reported that BLM interacts and colo-
calizes with the RMN complex (Wang et al., 2000) and re-
distributes at sites of replication fork arrest (Wang et al.,
2000; Bischof et al., 2001). Thus, we sought to determine
whether BS cells properly activated the RMN complex after
ionizing radiation–induced DNA damage or HU-induced
replication arrest. Focal localization of the RMN complex
was analyzed in wild-type, BS cells, and in cells from BS in
which the wild-type BLM-coding sequence was introduced
by transfection (Fig. 1).
Relocalization of the RMN complex, here visualized as
MRE11 and NBS1 focus-forming activity, was observed ei-
ther after HU or 
 
 
 
-rays in normal cells (Fig. 2, A and B). As
Figure 1. Phenotypic reversion of BS cells 
through introduction of a wild-type copy of the 
BLM cDNA. (A) Transfection of the BS lympho-
blasts GM03403 with a BLM-expressing plasmid 
resulted in the recovery of a normal SCE yield (a) 
compared with the unreverted cell line (b). (B) 
Table showing the SCE yield in the wild-type, BS 
and BS reverted cell lines. (C) Transfection of the 
BS lymphoblasts GM03403 with a BLM-expressing 
plasmid resulted in the recovery of the expression 
of the BLM protein. 
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Figure 2. RMN complex relocalization in 
response to replication arrest is defective in BS 
cells. (A) Normal (SNW646 and GM3657), BS 
(GM09960 and GM03404), and the revertant 
cells (GM03403BLM) were either treated with 2 
mM HU or with 10 Gy of  -rays and processed 
for immunofluorescent staining with MRE11 
and NBS1 antibodies at the indicated time 
points after treatment. The percentage of cells 
displaying RMN foci was calculated after 
scoring 200 nuclei for each time point. Data are 
the mean   the standard deviation of three
independent experiments. (B) Representative 
pattern of MRE11 and NBS1 relocalization after 
HU or 10 Gy of  -rays in wild-type (GM3657), 
BS (GM03403), and GM03403BLM cells. It is 
possible to note that BS cells did not contain 
foci after HU treatment, whereas they are 
detected after  -rays. Images were taken from 
cells harvested at 6 h after treatment, but similar 
results were observed at the other harvesting 
times in which relocalization was detected. (C) 
Analysis of NBS1 phosphorylation in wild-type 
(GM3657), BS (GM09960), and revertant 
GM03403 cells in response to 2 mM HU or 10 
Gy of  -rays. Cells were lysed 2 h after treat-
ments, and protein extracts were separated on 
7.5% SDS-PAGE gel. Blot membrane was 
probed with NBS1 antibody (Novus Biologicals). 
Ponceau Red staining of the blot assessed equal 
loading and transfer. 
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Figure 3. MRE11 complex relocalization in response to replication arrest is normal in WS cells. (A) Normal (SNW646) and WS (AG14426 
and KO375) were either treated with 2 mM HU or with 10 Gy of  -rays and processed for immunofluorescent staining with MRE11 antibody 
(GenTex; 1:500) at the indicated time points after treatment. The percentage of cells displaying MRE11 foci was calculated after scoring 200 
nuclei for each time point. Data are the mean   the standard deviation of three independent experiments. (B) Representative pattern of MRE11 
complex relocalization after HU or 10 Gy of  -rays in WS cells (AG14426).
Figure 4. BS cells arrest and resume correctly 
DNA synthesis after HU treatment. (A) Normal 
(GM3657), BS (GM0343) and BS revertant cells 
(GM03403BLM) were exposed to 2 mM HU and 
harvested at the indicated times. Alternatively, 
Normal (GM3657), BS (GM0343), and BS revertant 
cells (GM03403BLM) were exposed to 2 mM HU 
for 2 h and recovered at the indicated times in 
drug-free medium (B). Percentage of S-phase cells 
was determined labeling DNA synthesis by adding 
BrdUrd in the last hour before harvesting. BrdUrd 
incorporation was assessed as described in Materials 
and methods. Similar results were obtained also 
with the other normal (GM3657 and AHH1) and 
BS (GM09960) cells. Points represent mean   SE 
from at least three experiments. Replication blockage 
by HU leads to the induction of apoptotic cell 
death (C) and micronuclei (D) in BS. Normal 
(SNW646, AHH1 and GM3657), BS (GM09960 
and GM03404), and the BS revertant cells 
(GM03403BLM) were exposed to 2 mM of HU 
and harvested at different time points. The 
induction of apoptotic and micronucleated nuclei 
was evaluated at the indicated time by bis-benzimide 
staining of cells smeared onto microscopic slides 
as described in Materials and methods. For the 
analysis of the apoptotic cell death similar results 
were obtained by TdT-mediated end-labelling 
assay. Points represent mean   SE from at least 
three experiments. 
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expected, MRE11 and NBS1 foci colocalized (Fig. 2 B), and
each separately colocalized with RAD50 (unpublished data).
Therefore, we feel confident that each of the three foci rep-
resents the activity of the whole complex. RMN complex fo-
calization appeared time dependent, reaching the top value
at 6 h after treatment with 
 
 
 
-rays or HU, and showing a
similar kinetic in both the two normal cell lines tested. In
contrast, MRE11 and NBS1 foci were not observed in BS
cells after HU treatment. However, BS cells were able to
correctly relocalize the RMN complex after 
 
 
 
-rays, suggest-
ing that the absence of an active BLM protein impaired
RMN focus-forming activity, specifically after replication
fork arrest. Interestingly, introduction of a wild-type BLM-
expressing plasmid completely restored the ability of BS cells
to form RMN foci after HU treatment (Fig. 2, A and B).
Focalization of the RMN complex has been correlated to
NBS1 phosphorylation, and such a modification is consid-
ered a prerequisite or a consequence of the complex subnu-
clear relocalization (Zhao et al., 2000; Gatei et al., 2001;
Mirzoeva and Petrini, 2001). Consistent with the immuno-
cytochemical data, we found that NBS1 dephosphorylated
in BS cells after HU exposure, but not after 
 
 
 
-rays (Fig. 2
C). Interestingly, the MRE11 complex is properly relocal-
ized after HU and 
 
 
 
-rays in cells mutated in another RecQ-
like helicase, WRN (Fig. 3, A and B).
Because RMN complex has been correlated with check-
point activation in the S-phase of the cell cycle after ionizing
radiation–induced DNA damage (Petrini, 2000), and given
that HU specifically interferes with the S-phase progression,
we investigated whether in BS cells the absence of RMN fo-
cal localization could determine deficiency in the arrest of
DNA synthesis after HU treatment. Analysis of the rate of
Figure 5. In BS cells, BRCA1 activation and relocalization is normal in response to replication arrest or ionizing radiation-induced DNA 
damage. Normal (SNW646 and GM3657), BS (GM03403), and the BS revertant cells (GM03403BLM) were either treated with 2 mM HU or 
with 10 Gy of  -rays and processed for immunofluorescent staining with BRCA1 antibody at the indicated time points after treatment (A). The 
percentage of cells displaying BRCA1 foci was calculated after scoring 200 nuclei for each time point. Data are the mean   the standard 
deviation of three independent experiments. (B) Representative pattern of BRCA1 relocalization after HU or 10 Gy of  -rays in wild-type 
(GM3657), BS (GM03403), and GM03403BLM cells. Images were taken from cells harvested at 8 h after treatment, but similar results were 
observed at the other harvesting times in which relocalization was detected. (C) Analysis of BRCA1 phosphorylation in wild-type (GM3657), 
BS (GM03403), and revertant GM03403 cells in response to 2 mM HU or 10 Gy of  -rays. Cells were lysed 2 h after treatments and protein 
extracts were separated on 5% SDS-PAGE gel. Blot membrane was probed with BRCA1 antibody (Oncogene). Ponceau red staining of the 
blot assessed equal loading and transfer. 
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5
 
 
 
-bromo-2-deoxyuridine (BrdUrd) incorporation after HU
treatment revealed that BS cells normally arrested and re-
sumed DNA replication, even if with a slower rate (Fig. 4, A
and B), suggesting that RMN complex is not crucial for the
S-phase checkpoint activation after replication arrest. How-
ever, treatment with HU resulted in a higher apoptotic cell
death in BS cells, as well as in a 
 
 
 
4-fold higher induction of
micronuclei compared with normal cells. It is important to
note that hypersensitivity to HU was corrected by transfec-
tion of wild-type BLM (Fig. 4, C and D).
These results suggest that BLM protein is needed to the
correct subnuclear assembly of the RMN complex after rep-
lication fork stall, possibly resulting in a protection against
cell death and chromosomal damage.
 
BLM protein is not required for correct formation of 
BRCA1 foci after both HU and 
 
 
 
-irradiation
 
Because BRCA1 interacts with both the RMN complex and
BLM (Zhong et al., 1999; Wang et al., 2000), and given
that there are conflicting results on its requirement in RMN
focal localization after DNA damage (Zhong et al., 1999;
Wang et al., 2000; Wu et al., 2000a), we investigated
whether BRCA1 activation was normal in BS cells after HU
or 
 
 
 
-rays treatments. In agreement with previously reported
data (Scully et al., 1997; Wang et al., 2000), BRCA1 formed
nuclear foci in normal cells either after HU or 
 
 
 
-rays (Fig. 5,
A and B) and these foci correctly colocalized with compo-
nents of the RMN complex or with RAD51, the strand-
exchange protein involved in HR (unpublished data). Inter-
estingly, despite the fact that BLM and BRCA1 colocalize
(Wang et al., 2000), lack of BLM did not result in an im-
paired capability of BRCA1 to form foci. In fact, BRCA1
was normally relocalized after 
 
 
 
-rays or HU in BS cells (Fig.
5, A and B). It has been previously reported that BRCA1
subnuclear assembly requires phosphorylation by either the
ATM and ATR kinases (Cortez et al., 1999; Tibbetts et al.,
2000; Gatei et al., 2001). Thus, to expand our observations
we also determined the phosphorylation state of BRCA1 in
BS compared with normal cells. As expected, BRCA1 was
found phosphorylated in normal cells after ionizing radia-
tion or HU, and a similar result was observed in BS cells
(Fig. 5 C).
These results show that absence of RMN complex for-
mation in BS cells after HU is not attributable to a defect
in BRCA1 phosphorylation/relocalization, and suggest that
BLM is not required for proper subnuclear localization of
the BRCA1 protein.
 
BLM protein is phosphorylated after HU exposure in 
an ATR-dependent manner
 
It has been reported that BLM is phosphorylated after 
 
 
 
-rays
in a ATM-dependent manner (Ababou et al., 2000), there-
fore we investigated the possibility that BLM could be simi-
larly modified after HU treatment, and whether such a
modification could correlate with the subnuclear assembly
of the RMN complex after replication fork arrest.
We found BLM modified in response to HU-induced rep-
lication arrest, resulting in the appearance of a slower-migrat-
ing form that was already detectable after 1 h of treatment
and persisted up to 8h (Fig. 6 A; unpublished data). In vivo
labeling experiments using [
 
32
 
P]-ortophosphate showed that
immunoprecipitated BLM was radiolabeled, clearly demon-
strating that BLM was phosphorylated after HU. In addi-
tion, the slower-migrating form was easily converted into the
faster-migrating form by phosphatase treatment, confirming
that BLM was actually phosphorylated after HU (Fig. 6 B).
Consistent with the data reported by others (Ababou et al.,
2000), BLM was also found phosphorylated after 
 
 
 
-rays
(Fig. 6 B). We then tested the possibility that the HU-
dependent phosphorylation of BLM could also be under the
control of ATM by analyzing BLM phosphorylation in AT
Figure 6. BLM phosphorylation in response to replication arrest is 
ATM-independent but ATR dependent. Wild-type cells (SNW646) 
were starved for phosphate for 30 min, and then labeled with 
[
32P]-orthophosphate and treated with 2 mM HU for the indicated 
time before extraction and immunoprecipitation. The protein levels 
and phosphorylation were analyzed by Western blotting and auto-
radiography, respectively. Immunoprecipitated were separated on 
5% SDS-PAGE gels. Blot membranes were probed with BLM 
antiserum. Proteins extracted from mock-, HU- (2 mM, 2 h), or 
 -rays–treated cells (10 Gy, 2 h), or wild-type (GM3657, Panel B), 
AT (GM2782, Panel C), or ATRKd cells (Panel D) were immunopre-
cipitated using BLM antisera. BLM immunoprecipitated from 
untreated and treated wild-type, AT, or ATRKd cells were incubated 
in the absence ( ) or in the presence ( ) of lambda phopshatase 
(PPase). All extracts were separated on 5% SDS-PAGE gels (30 V for 
16 h at 4 C) and blot membranes were probed with BLM antiserum. 
Ponceau red staining of the blot assessed equal loading and transfer. 
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cells. Interestingly, BLM phosphorylation was absent in AT
cells after ionizing radiation but was not abolished after HU
treatment (Fig. 6 C), suggesting that kinases other than
ATM could phosphorylate BLM in response to replication
fork arrest. The ATR kinase has been reported to be crucial
in the modification of several proteins after replication fork
stall (Shiloh, 2001); therefore, we sought to determine
whether ATR could be involved in BLM modification after
HU. In order to test this possibility, we exposed cells express-
ing an ATR dominant negative mutant form (ATRKd)
(Cliby et al., 1998) to HU or 
 
 
 
-rays. BLM phosphorylation
was not observed after HU, whereas it was apparently nor-
mal after 
 
 
 
-rays exposure (Fig. 6 D). Interestingly, treatment
of cells with dose levels of Wortmannin resulting only in the
inhibition of DNA-PK activity (Sarkaria et al., 1998, 1999)
did not affect the phosphorylation state of BLM either after
 
 
 
-rays or HU (unpublished data).
These results suggest that BLM is phosphorylated after rep-
lication fork arrest through an ATR-dependent mechanism.
 
BLM foci after HU are formed independently 
by phosphorylation
 
Phosphorylation of BLM by ATM does not seem to be im-
portant for its subnuclear assembly, as BLM foci are found
in AT cells (Bischof et al., 2001), so we investigated whether
phosphorylation was essential for BLM focus-forming activ-
ity after HU treatment.
Ionizing radiation and HU-induced BLM relocalization
was analysed in normal and AT cells, and in cells expressing
a dominant negative inactive form of the ATR kinase. We
found that the percentage of nuclei with BLM foci and the
number of foci per nucleus increased in ATRKd and AT
cells after HU treatment (Fig. 7, A and B). Consistent with
previous reports (Bischof et al., 2001), a higher number of
BLM-positive nuclei was found in AT cells, also after HU
treatment (Fig. 7, A and B). Interestingly, almost all the
BLM foci were found in MRE11-positive cells after 4 h HU
of treatment with 
 
 
 
50% of foci colocalizing (Fig. 8 A and
Table I). These results show that BLM phosphorylation by
Figure 7. BLM focal localization occurs also in the absence of phosphorylation. (A) Normal (SNW646 and GM3657), ATRwt, ATRKd and 
AT cells (GM2782 and GM3189) were either treated with 2 mM HU or with 10 Gy of  -rays and processed for immunofluorescent staining 
with BLM antibody at the indicated time points after treatment. The percentage of cells displaying BLM foci was calculated after scoring 200 
nuclei for each time point. Data are the mean   the standard deviation of three independent experiments. (B) Table summarizing the number 
of BLM-positive nuclei and BLM foci/nucleus in wild-type (SNW646), ATRKd and AT (GM3189) cells. The values are the mean   the SD 
from three independent experiments. (C) Representative pattern of BLM relocalization after HU or 10 Gy of  -rays in wild-type (GM3657), 
ATRKd and AT (GM3189) cells. Images were taken from cells harvested at 4 h after treatment but similar results were observed at the other 
harvesting times in which relocalization was detected. 
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ATR after replication fork arrest is not important for its re-
localization.
 
BLM phosphorylation is important for formation of the 
RMN complex after HU
 
In order to investigate whether BLM phosphorylation after
HU was correlated to the relocalization of the RMN com-
plex at sites of replication fork stall, we examined MRE11
focus-forming activity in ATRKd cells.
We found that overexpression of an inactive dominant
negative form of ATR prevented, almost completely, forma-
tion of MRE11 nuclear foci after HU treatment (Fig. 9, A
and B). MRE11 foci were found at a rather normal level in
AT cells (Fig. 9, A and B; unpublished data), in agreement
with previously reported data (Maser et al., 1997; Mirzoeva
and Petrini, 2001), and in cells overexpressing a wild-type
form of ATR (ATRwt). Because ATR function has been re-
ported to mediate multiple checkpoint response (Shiloh,
2001), we test the possibility that the observed impaired re-
localization of the RMN complex in ATRKd cells should be
a secondary effect of S-phase checkpoint release. Hence, we
measured the number of cells in S-phase after treatment
with HU in ATRwt and ATRKd cells. We found that over-
expression of the ATR inactive form did not largely affect
the S-phase arrest imposed by HU (Fig. 9 C), suggesting
that this checkpoint response is mainly mediated by ATR/
ATM-independent mechanisms as previously reported (Guo
et al., 2000). Thus, the observed effect on the assembly of
the RMN complex of ATR inhibition is unlikely associated
to S-phase checkpoint override.
Our results indicate a positive correlation between that
ATR-dependent phosphorylation of BLM and accurate sub-
nuclear relocalization of the RMN complex in response to
HU treatment.
 
Discussion
 
BLM protein seems to be important in maintaining ge-
nomic stability; in fact, BS cells show increased rates of ho-
mologous recombination and possibly an aberrant resolu-
tion of such events. However, the precise functions of BLM
helicase remain to be fully elucidated. BLM protein is found
associated with several proteins involved in genome stability,
such as RAD51, PML, MLH1, and also BRCA1 and the
RMN complex, to form the so-called BASC complex (Wang
et al., 2000; Hu et al., 2001; Langland et al., 2001; Wu et
al., 2001). The association of BLM with BASC is thought to
be important as a surveillance system, in order to recognize
anomalous structures in DNA (Wang et al., 2000).
In this study, we have shown for the first time that BLM is
required for correct relocalization of the RMN complex at
sites of stalled replication fork after HU treatment. In addi-
tion, we have provided evidence that cellular localization of
the RMN complex is correlated with BLM subnuclear redis-
tribution and its phosphorylation by the ATR kinase. On
the contrary, we demonstrated that BLM is not important in
the focal localization of the RMN complex after 
 
 
 
-rays, and
that BRCA1 relocalization does not necessitate BLM activ-
ity. Our findings of an essential role of BLM in loading
other factors, such as the RMN complex, at sites of replica-
tion fork stall should be consistent with a role of BLM in
recognizing abnormal structures at the stalled replication
machinery. A similar role has been proposed for the yeast
orthologue of BLM, SGS1 (Frei and Gasser, 2000). Accord-
ingly, it has been reported that BLM helicase can bind Hol-
liday junctions (Karow et al., 2000; van Brabant et al.,
2000) and other structures that could arise from replication
fork blockage (Mohaghegh et al., 2001). In this context, the
recruitment of the RMN complex could assist BLM helicase
in the resolution of abnormal structures at the stalled repli-
Figure 8. BLM foci colocalizes early 
with the RMN complex after HU-
induced replication arrest. Normal, 
wild-type cells (GM3657) were mock 
treated or exposed to 2 mM HU for the 
indicated time, and then processed for 
double immunofluorescent staining 
with either MRE11 antibody and BLM 
polyclonal antiserum. The percentage 
of cells positive for the indicated
double staining was calculated after 
scoring 50 nuclei for each time point. 
Images were handled as described in 
Materials and methods. Nuclei were 
considered positive for the colocalization if at least one third of the foci showed colocalization as judged by a yellow-orange 
appearance in the merged image.
 
Table I. Colocalization of BLM with RMN or BRCA1 foci after replication arrest
 
2 mM HU (h)
BLM/RMN-positive nuclei 
(%of total BLM-positive nuclei)
RMN/BRCA1-positive nuclei 
(%of total RMN-positive nuclei)
BLM/BRCA1-positive nuclei 
(%of total RMN-positive nuclei)
 
22 00 0
4 8 51 31 2
6 2 47 52 3 
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cation forks after their recognition. In fact, the RMN com-
plex itself presents characteristics, such as the exonuclease
and endonuclease activities (Haber, 1998), that could be im-
portant in resolution of aberrant replication forks. There-
fore, MRE11 complex has been reported to be important in
dealing with UV-induced replication arrest in some circum-
stances (Limoli et al., 2000) and, very recently, Maser and
colleagues (2001) demonstrated a possible role for the RMN
complex during replication. From this point of view, the
possible association of a helicase, BLM, with the RMN com-
plex after replication arrest could actually represent, func-
tionally, the mammalian analogue of the bacterial RecBCD
complex (Connelly et al., 1998). Bacteria replication restart,
after fork stall, requires the RecBCD complex and RecA.
However, in the absence of an active RecBCD complex, rep-
lication fork stall is resolved through the action of resolvases,
resulting in the formation of double-strand breaks, which
trigger homologous recombination (Michel et al., 2001). In
fission yeasts, the RecQ helicase, Rqh1, was proposed to re-
move abnormal structures formed at stalled replication forks
in a nonrecombinogenic way, by reversed forks reaction
(Doe et al., 2000). In the absence of Rqh1, the reversed fork
would be processed only through recombination. Accord-
ingly, the absence of an active BLM could result in an un-
corrected resolution of the abnormal structures at the stalled
replication fork, which possibly forces cells to use a RAD51-
dependent mechanism of replication fork repair, giving rise
to genetic instability, rearrangements, and possibly cell
Figure 9. BLM phosphorylation is required to relocalize the RMN complex after replication fork stall. (A) Cells overexpressing the wild-type 
(ATRwt) or the inactive form (ATRKd) of the ATR kinase were treated with 2 mM HU for the indicated times and then processed for 
immunofluorescent staining with MRE11 antibody. The percentage of cells displaying MRE11 foci was calculated after scoring 200 nuclei
for each time point. Data are the mean   the standard deviation of three independent experiments. (B) Representative pattern of MRE11 
relocalization after HU in the absence or presence of ATR-mediated BLM phosphorylation. The cells used were the GM3657 (wild-type), the 
ATRwt, the ATRKd and the GM3189 (AT). MRE11 foci were not detected in cells overexpressing the inactive form of ATR after HU treatment, 
whereas were observed in AT cells (panel B, third and fourth rows). Images were taken from cells harvested at 4 h after treatment, but similar 
results were also observed at 2 h. (C) Overexpression of the kinase-inactive form of ATR did not result in abrogation of the HU-imposed 
S-phase replication checkpoint. Cells overexpressing wild-type (ATRwt) and kinase inactive (ATRKd) form of ATR were mock treated or 
exposed to 2 mM HU and harvested at the indicated time. Percentage of S-phase cells was determined labeling DNA synthesis by adding 
BrdUrd in the last hour before harvesting. BrdUrd incorporation was assessed as described in Materials and methods. Similar results as shown 
for the ATRwt cells were obtained with other cell lines expressing the ATR kinase at a normal level (GM3657 and SNW646). Points represent 
mean   SE from at least three experiments. (D) Proposed model of action of BLM, RMN complex, ATR, and BRCA1 in the resolution of 
stalled replication forks. 
28 The Journal of Cell Biology 
 
|
 
 
 
Volume 157, Number 1, 2002
 
death. Consistent with such possibility, the RAD51 re-
sponse in BS cells is found to be unusually elevated (Wu et
al., 2001), and a higher yield of apoptotic and micronucle-
ated cells are also observed after replication arrest (Fig. 4).
These events would result from deregulated recombination,
as observed in the Sgs1 yeast mutants or in cells from
Werner’s syndrome (WS), which lack the WRN protein
(Gangloff et al., 2000; Pichierri et al., 2001). However, in
WS cells, apoptotic cell death was specifically observed in
cells engaged in recombination, thus resulting in depletion
of RAD51-positive nuclei, whereas in BS, such a depletion
of RAD51-positive cells is not observed (Wu et al., 2001;
unpublished data). Such an observation suggests a role for
BLM soon after replication arrest, rather than a role in con-
trolling the correct resolution of RAD51-dependent recom-
bination events. Moreover, WS cells are able to assemble the
MRE11 complex in a manner that is indistinguishable from
the wild-type, suggesting further that WRN and BLM heli-
cases perform different and nonoverlapping roles in the cells.
Furthermore, BLM foci are detected starting at 2 h after rep-
lication arrest, whereas RAD51 foci are observed from 6 to
10 h (Pichierri et al., 2001; unpublished data).
Interestingly, the recruitment of the RMN complex, at
sites of replication arrest, requires not only BLM focus-
forming activity, but also the ATR kinase activity, as RMN
complex does not focalize when the ATR kinase is catalyti-
cally inactive but BLM is functional. Interestingly, we found
BS cells highly sensitive to HU like that expressing inactive
form of ATR (Cliby et al., 1998), supporting positively a
probable functional interaction between these two proteins.
It is noteworthy that an active BLM seems to be unnecessary
to the activation of BRCA1, either after 
 
 
 
-rays or HU, even
though BRCA1 and BLM helicase are activated by ATR in
response to stalled replication (Tibbetts et al., 2000, and this
study), and despite the fact that they colocalize after replica-
tion arrest (Wang et al., 2000). This actually suggests that
BLM and BRCA1 act during different steps of replication
fork repair. Further studies are needed to clarify the different
roles for these two proteins in the response to replication ar-
rest. However, it has been reported that a functional BRCA1
is not important for the activity of the RMN complex (Wu
et al., 2000a), and it seems that BRCA1 inhibits the activity
of the RMN complex (Paull et al., 2001).
Taken together, these findings could suggest a model (Fig.
9 D) in which BLM relocalizes (probably at sites of stalled
replication fork, soon after DNA synthesis blockage) and is
phosphorylated by ATR. BLM and the RMN complex
would promote resolution of the stalled replication fork and
rescue of the DNA synthesis in a nonrecombinogenic way.
It is possible that BRCA1 can function later to properly re-
solve replication fork arrest or to repair double-strand breaks
formed as a consequence of the absence of either BLM or
RMN relocalization, possibly cooperating with RAD51.
Consistently, we find that BLM focalization already occurs
at 2 h after HU, when we observe almost complete inhibi-
tion of DNA synthesis, whereas BRCA1 relocalization takes
place later. Also, the RMN complex is recruited at sites of
replication arrest shortly, showing the maximum of colocal-
ization with BLM at 4 h after replication arrest, whereas
colocalization with BRCA1 is highest at 6 h. Interestingly,
the peak of BRCA1 and RAD51 colocalization has been re-
ported only at 8–12 h after treatment (Zhong et al., 1999;
unpublished data), actually suggesting a later role for this
complex in recombination and arguing for our model.
In conclusion, this study establishes a regulatory relation-
ship between BLM, ATR, and the RMN complex in the re-
sponse to replication fork arrest and collapse raising the pos-
sibility that they perform a coordinate action ensuring
genomic stability in human cells.
 
Materials and methods
 
Cell lines
 
We used three normal (SNW646, GM3657, and AHH1), two BS
(GM09960 and GM03403), and two WS (KO375 and AG14426) EBV-
transformed lymphoblasts. SNW646 and KO375 lymphoblasts were a gift
of Dr. V.A. Bohr (National Institutes of Health, Baltimore, MD), whereas
BS, AG14426, and GM3657 normal lymphoblasts were from Coriell Cell
Repositories. EBV-transformed lymphoblasts from two ataxia telangiectasia
donors (GM02782 and GM03189) were provided by Dr. F. Rosselli
(CNRS, Villejuif, France). Cell lines overexpressing the kinase-dead or
wild-type form of ATR kinase (ATRKd and ATRwt, respectively) have been
described elsewhere (Cliby et al., 1998). The GM03403 cell line was phe-
notypically reverted (GM03403
 
BLM
 
) through transfection with a linear-
ized pREP4 plasmid (Invitrogen) containing the wild-type 
 
BLM
 
 cDNA.
GM03403 cells contain a frameshift mutation leading to the expression of
a truncated BLM protein (Ellis et al., 1995). According to Dutertre et al.
(2000), we have not been able to detect this truncated protein by Western
blotting. However, we were able to detect wild-type BLM protein in phe-
notypically reverted cells (Fig. 1 C). Functional complementation in
GM03403
 
BLM
 
 was verified by analyzing the SCEs levels (Fig. 1, A and B).
All lymphoblastoid cell lines were routinely maintained in exponential
growth in RPMI 1640 medium (Life Technologies) supplemented with 10–
15% heat-inactived fetal calf serum (Boehringer Mannheim) by a daily di-
lution to 3.5 
 
  
 
10
 
5
 
 cells/ml; GM03403
 
BLM
 
 cells were grown in the pres-
ence of 200 
 
 
 
g/ml of G418 (Sigma-Aldrich). The ATRwt and ATRkd cells
were grown in DME medium (Life Technologies) supplemented with 15%
fetal calf serum (Hyclone) in the presence of 400 
 
 
 
g/ml of G418 (Sigma-
Aldrich). Expression of the transgene was achieved by the addition of 1
 
 
 
M deoxycycline (Sigma-Aldrich) for 48 h.
 
Chemicals and treatments
 
HU (Sigma-Aldrich) was added from a stock solution (200 mM in PBS) and
left in the cultures until harvesting. Alternatively, cells were exposed to
 
 
 
-rays from a 
 
60
 
Co source at a dose rate of 2 Gy/min. Because we did not
observe a significantly higher sensitivity of BS cells towards ionizing radia-
tion–induced DNA damage, either in terms of apoptotic cell death or cell
survival (unpublished data), we have chosen to use a dose level of 10 Gy,
corresponding to 
 
 
 
10% of cell survival either in normal or BS cells. This
dose level is widely to investigate relocalization of proteins involved in
DNA repair and/or DNA damage signalling. After 
 
 
 
-ray exposure, cells
were cultured in complete medium at 37
 
 
 
C until being processed.
 
Sister chromatid exchanges analysis
GM3657, GM03403, and GM03403BLM cells were grown in the presence
of 3  g/ml BrdUrd and metaphase cells collected after 48 h by adding col-
cemid (0.2  g/ml) in the last 4 h. Slides prepared according to standard
techniques were stained by 10  g/ml Hoechst for 20 min to visualize
SCEs. 50 metaphase cells for each experimental point were scored.
Evaluation of the apoptotic response
Apoptotic and abnormal nuclear morphology was determined as previ-
ously described (Pichierri et al., 2001). Apoptosis was also visualized using
the TdT-mediated end-labelling assay using the In Situ Cell Death Detec-
tion Kit (Roche Molecular Biochemicals) according to the procedure indi-
cated by the manufacturer for analysis on slides. Results obtained with the
two different methods were similar.
Immunofluorescence
Cells harvested at the indicated time were spread onto poly-L-lysine–
coated slides and fixed as previously described (Pichierri et al., 2001).
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clonal anti-MRE11 (Novus BioLabs), mouse monoclonal anti-MRE11 (Gen-
Tex), mouse monoclonal anti-RAD50 (GenTex), rabbit polyclonal anti-
NBS1 (Novus BioLabs), or mouse monoclonal anti-BRCA1 (Oncogene
Research) was performed overnight at 4 C in PBS/1% BSA, whereas
specie-specific fluorescein- or Texas red–conjugated secondary antibodies
(Jackson ImmunoResearch Laboratories) were applied for 1 h at room tem-
perature, followed by counterstaining for 5 min at room temperature with
0.5  g/ml DAPI. All the primary antibodies were used at a 1:300 dilution,
whereas the secondary antibodies were employed at a 1:500 dilution.
Slides were mounted in Vectashield (Vector Labs) and analyzed by a Zeiss
fluorescence confocal microscopy or through a Leica epifluorescence mi-
croscope equipped with a CCD camera. Images were acquired as grey-
scale files using the Metaview software, and then pseudocolored and
merged using Adobe Photoshop. For each time point, at least 200 nuclei
were examined, and BLM, BRCA1, or MRE11-NBS1 foci were scored at a
100  magnification using the epifluorescence microscope. Only nuclei
showing  5 foci were considered positive. Parallel samples, incubated ei-
ther with the appropriate normal serum or only with the secondary anti-
body, confirmed that the observed fluorescence pattern was not attribut-
able to artefacts.
Recovery of DNA synthesis after HU treatment
In order to verify whether BS cells properly arrest DNA synthesis after HU
treatment, cells were exposed to 2 mM HU and harvested in drug-free me-
dium for different time points, BrdUrd (30  g/ml) was added 1 h before
harvesting, and BrdUrd incorporation was evaluated as previously de-
scribed (Franchitto et al., 1998). At least 500 interphase cells were scored
to evaluate the percentage of labeled nuclei. Only nuclei displaying a
more or less uniform BrdUrd labeling in the entire volume were consid-
ered as actively replicating.
The percentage of cells undergoing DNA synthesis at each time point
was calculated as fraction of the treated cells versus untreated controls.
Immunoprecipitation and Western blot analysis
Cells (10
7) were collected by low-speed centrifugation, washed in PBS,
and lysed in standard RIPA buffer (PBS, 1% NP-40, 0.5% Na-Deoxycho-
late, 0.1% SDS, 10  g/ml Aprotinin, 10  g/ml PMSF, 1 mM Na orthovana-
date, and 1 mM NaF). Cell lysates (20  g) were resolved by SDS-PAGE and
transferred to nitrocellulose (PROTRAN; Schleicher & Schuell). Equal load-
ing and transfer was monitored by Ponceau red staining of the membrane.
Blots were separately incubated overnight at 4 C with primary antibod-
ies against NBS1 (1:2,000), MRE11 (1:2,000), BLM (1:1,000), or BRCA1
(1:100). Horseradish peroxidase–conjugated goat specie-specific second-
ary antibodies (Santa Cruz Biotechnology) were used at a dilution of
1:1,000, and visualization of the signal was accomplished using ECL plus
(Amersham Pharmacia Biotech).
In immunoprecipitation experiments, cells (15   10
7) were lysed in a
mild lysis buffer (50 mM Tris/HCl, pH 8, 300 mM NaCl, 10 mM MgCl2, 1
mM EDTA, 25 mM  -glycerophosphate, and 0.5% Igepal-40), including
protease and phosphatase inhibitors (10  g/ml leupeptin, 10  g/ml aproti-
nin, 10  g/ml PMSF, 1 mM Na orthovanadate, and 1 mM NaF). 300  g of
lysate were precleared with Sepharose protein A/G beads, and then incu-
bated overnight at 4 C with anti-BLM antibodies and Sepharose protein A/G
beads. After extensive washing in mild lysis buffer, BLM-containing immu-
noprecipitates were boiled in electrophoresis sample buffer and analyzed
by immunoblotting. For phosphatase treatments, immunoprecipitates were
resuspended in phosphatase buffer and incubated for 30 min with 300
units of lambda phosphatase (New England BioLabs) at 30 C, and then
boiled in electrophoresis sample buffer prior to Western blotting analysis.
32P in vivo labeling
In vivo labeling experiments used exponentially growing wild-type cells
(SNW646). The cells were washed with phosphate-free RPMI1640 me-
dium, supplemented with 10% heat-inactived fetal calf serum, and incu-
bated for 30 min at 37 C in the same media. [
32P]-orthophosphate (Amer-
sham Pharmacia Biotech) was added directly to the medium (0.6 mCi/ml).
After a 30-min incubation at 37 C, cells were either mock treated or ex-
posed to 2 mM HU for different time periods. The cells were lysed as de-
scribed above, and BLM was immunoprecipitated using 3  l rabbit anti-
BLM antiserum (Novus Biologicals). The immunoprecipitated proteins
were resolved by SDS-PAGE, and analyzed by autoradiography and West-
ern blotting.
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